Instem Acquires Xybion Digital from Banerjee Group LLC

Xybion Digital Acquires Autoscribe Limited for US$15M

November 16, 2023

Software

Xybion Digital Inc. completed the acquisition of Autoscribe Limited, a UK‑headquartered LIMS software company, for an aggregate purchase price of US$15 million (US$12.094M at closing plus three deferred US$1M payments). The acquisition was funded in part by a new up-to US$15M senior secured credit facility arranged with Capital Finance Opportunities 2303F LLC; Autoscribe reported roughly US$6.18M revenue and an adjusted EBITDA of US$0.678M for the fiscal year ended March 31, 2023.

Instem Acquires RockStep Solutions (Climb)

July 28, 2025

Software

Instem has closed the acquisition of RockStep Solutions, the developer of Climb, a cloud-based non-GLP preclinical study management platform. The deal integrates Climb into Instem’s Provantis suite to provide an end-to-end preclinical solution spanning early discovery, non-GLP and GLP study management and regulatory submission.

Bruker Corporation Acquires Nion

January 3, 2024

Manufacturing

Bruker Corporation has acquired Nion, a Kirkland, Washington developer and manufacturer of high-end scanning transmission electron microscopes (STEM), including the UltraSTEM line and advanced EELS technology. The acquisition strengthens Bruker's materials science instrumentation portfolio and provides capabilities for electron diffraction crystallography; Nion reported approximately $8 million in revenue in 2023. Financial terms were not disclosed.

Summa Equity Acquires Majority Stake in Axion BioSystems

July 15, 2021

Medical Devices

Summa Equity Fund II has acquired a majority stake in Axion BioSystems, a US life science tools company that develops MEA (microelectrode array) and impedance-based bioelectronic assay technologies. Summa plans to support Axion's commercial scale-up and global growth to accelerate adoption of its platforms across academia and biopharma, particularly in cell and gene therapy and drug discovery applications.

Cancer Genetics (Vyant Bio) Acquires StemoniX

March 31, 2021

Biotechnology

Cancer Genetics, Inc. completed a merger with StemoniX, Inc. and renamed the combined company Vyant Bio, Inc., with the new ticker VYNT on Nasdaq. StemoniX will operate as a wholly-owned subsidiary as the combined business integrates human iPSC-derived biology, software and preclinical capabilities to create a unified drug discovery platform.

Agilent Technologies Acquires e-MSion

March 9, 2023

Medical Devices

Agilent Technologies has acquired e-MSion, the early-stage company behind the ExD cell electron capture dissociation (ECD) technology for benchtop mass spectrometers. The purchase brings e-MSion's ExD cell and associated tools into Agilent's life-sciences instrument portfolio to expand biopharma characterization capabilities and make ECD accessible to a broader set of labs.